Julie Chen

Julie Chen

Auto-generated profile, based on publicly available information

Julie Chen

Department of Biological Engineering, Massachusetts Institute of Technology

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
MZMeilin Zhu
Meilin Zhu
MTMegan W. Tse
Megan W. Tse
JWJuliane Weller
Juliane Weller
JCJulie Chen
Julie Chen
PBPaul C. Blainey
Paul C. Blainey
Antibiotic resistance is a worldwide and growing clinical problem. With limited drug development in the antibacterial space, combination therapy has emerged as a promising strategy to combat multidrug‐resistant bacteria. Antibacterial combinations can improve antibiotic efficacy and suppress antibacterial resistance through independent, synergistic, or even antagonistic activities. Combination therapies are famously used to treat viral and mycobacterial infections and cancer. However, antibacterial combinations are only now emerging as a common treatment strategy for other bacterial infections owing to challenges in their discovery, development, regulatory approval, and commercial/clinical deployment. Here, we focus on discovery—where the sheer scale of combinatorial chemical spaces represents a significant challenge—and discuss how combination therapy can impact the treatment of bacterial infections. Despite these challenges, recent advancements, including new in silico methods, theoretical frameworks, and microfluidic platforms, are poised to identify the new and efficacious antibacterial combinations needed to revitalize the antibacterial drug pipeline.

31 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
STSri Gowtham Thakku
Sri Gowtham Thakku
JLJackson Lirette
Jackson Lirette
KMKanagavel Murugesan
Kanagavel Murugesan
JCJulie Chen
Julie Chen
GTGrant Theron
Grant Theron
DHDeborah T. Hung
Deborah T. Hung
Detection of microbial cell-free DNA (cfDNA) circulating in the bloodstream has emerged as a promising new approach for diagnosing infection. Microbial diagnostics based on cfDNA require assays that can detect rare and highly fragmented pathogen nucleic acids. We now report WATSON (Whole-genome Assay using Tiled Surveillance Of Nucleic acids), a method to detect low amounts of pathogen cfDNA that couples pooled amplification of genomic targets tiled across the genome with pooled CRISPR/Cas13-based detection of these targets. We demonstrate that this strategy of tiling improves cfDNA detection compared to amplification and detection of a single targeted locus. WATSON can detect cfDNA from Mycobacterium tuberculosis in plasma of patients with active pulmonary tuberculosis, a disease that urgently needs accurate, minimally-invasive, field-deployable diagnostics. We thus demonstrate the potential for translating WATSON to a lateral flow platform. WATSON demonstrates the ability to capitalize on the strengths of targeting microbial cfDNA to address the need for point-of-care diagnostic tests for infectious diseases.

24 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MTMegan W. Tse
Megan W. Tse
MZMeilin Zhu
Meilin Zhu
BPBenjamin Peters
Benjamin Peters
EHEfrat Hamami
Efrat Hamami
JCJulie Chen
Julie Chen
PBPaul C. Blainey
Paul C. Blainey
Antibiotic resistance, especially in multidrug-resistant ESKAPE pathogens, remains a worldwide problem. Combination antimicrobial therapies may be an important strategy to overcome resistance and broaden the spectrum of existing antibiotics. However, this strategy is limited by the ability to efficiently screen large combinatorial chemical spaces. Here, we deployed a high-throughput combinatorial screening platform, DropArray, to evaluate the interactions of over 30,000 compounds with up to 22 antibiotics and 6 strains of gram-negative ESKAPE pathogens, totaling to over 1.3 million unique strain-antibiotic-compound combinations. In this dataset, compounds more frequently exhibited synergy with known antibiotics than single-agent activity. We identified a compound, P2-56, and developed a more potent analog, P2-56-3, which potentiated rifampin (RIF) against antibiotic-resistant strains of Acinetobacter baumannii and Klebsiella pneumoniae . Using phenotypic assays, we showed P2-56-3 disrupts the outer membrane of A. baumannii . To identify pathways involved in the mechanism of synergy between P2-56-3 and RIF, we performed genetic screens in A. baumannii . CRISPRi-induced partial depletion of lipooligosaccharide transport genes ( lptA - D , lptFG ) resulted in hypersensitivity to P2-56-3/RIF treatment, demonstrating the genetic dependency of P2-56-3 activity and RIF sensitization on lpt genes in A. baumannii. Consistent with outer membrane homeostasis being an important determinant of P2-56-3/RIF tolerance, knockout of maintenance of lipid asymmetry complex genes and overexpression of certain resistance-nodulation-division efflux pumps—a phenotype associated with multidrug-resistance—resulted in hypersensitivity to P2-56-3. These findings demonstrate the immense scale of phenotypic antibiotic combination screens using DropArray and the potential for such approaches to discover new small molecule synergies against multidrug-resistant ESKAPE strains.

1 January 2004 in International Journal of Materials and Product Technology
Verified
Journal Article
Closed access
XLXiang Li
Xiang Li
James SherwoodJames Sherwood
James Sherwood
LLLu Liu
Lu Liu
JCJulie Chen
Julie Chen
Woven fabric composites made from commingled fibreglass and polypropylene fibres have the potential to make lightweight structural parts to replace metal structures in automobiles when competitively produced using thermostamping techniques. To expedite the acceptance of such composites, a credible design tool needs to be available to study the associated manufacturing process. For such a numerical method, a material model is required. Because the tows of the fabric are essentially inextensible, shear is the major deformation mode for assuming the stamped shape. The shear mechanical behaviour of fabric is obtained from a shear-frame test. A finite element model using a combination of truss and 2D solid elements is proposed. The truss elements represent the tows and use a nonlinear material model for capturing the increasing stiffness of the tows with increasing tensile strain. The 2D Solid elements capture the interaction between tows and the viscosity of the resin. The bias-extension test is a valuable test for investigating the shear performance of woven fabric composites. Using the finite element method, the bias-extension test is modelled, analysed and compared experimentally to verify the credibility of the woven-fabric material model.

6 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJulie Chen
Julie Chen
KPKatarina Pfeifer
Katarina Pfeifer
KSKerrin Steensen
Kerrin Steensen
ACAnne Marie Crooke
Anne Marie Crooke
MWMichael Wolfram
Michael Wolfram
PBPaul C. Blainey
Paul C. Blainey
While antibiotics mediate chemical warfare among microbes, their roles in the wild extend beyond direct growth inhibition( 1 ). Some antibiotics have the potential to mediate interference competition by triggering a bacterial stress response that subsequently activates endogenous viruses integrated in bacterial genomes (prophages). Canonically, this activation is regulated by the SOS response upon DNA damage. Here we show that a metabolite produced by natural isolates of Vibrio ordalii circumvents the SOS response by directly triggering prophage induction in other Vibrio species, co-occurring in the same environment. While the metabolite was previously classified as a broad-spectrum antibiotic, we observe how it acts as a peptide deformylase inhibitor that specifically induces certain prophages, even when target bacterial cells carry multiple other prophages. Its biosynthetic gene cluster, or ord cluster, also encodes its own peptide deformylase (OrdE) which provides self-immunity to producer strains. Likewise, among natural Vibrio isolates that carry similar prophages, resistance against the ord metabolite was found in those that had acquired a divergent second peptide deformylase. Finally, we show that prophage induction by the ord cluster prevents slower-growing producer strains from being outcompeted by their otherwise fast-growing competitors if they carry an inducible prophage. Thus, we demonstrate how natural products play additional impactful roles in communities beyond antibiotic activity and that prophage induction serves as an interference competition strategy, sustaining community diversity.

26 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMegan W. Tse
Megan W. Tse
MZMeilin Zhu
Meilin Zhu
BPBenjamin Peters
Benjamin Peters
EHEfrat Hamami
Efrat Hamami
JCJulie Chen
Julie Chen
PBPaul C. Blainey
Paul C. Blainey
Antibiotic resistance, especially in multidrug-resistant ESKAPE pathogens, remains a worldwide problem. Combination antimicrobial therapies may be an important strategy to overcome resistance and broaden the spectrum of existing antibiotics. However, this strategy is limited by the ability to efficiently screen large combinatorial chemical spaces. Here, we deployed a high-throughput combinatorial screening platform, DropArray, to evaluate the interactions of over 30,000 compounds with up to 22 antibiotics and 6 strains of Gram-negative ESKAPE pathogens, totaling to over 1.3 million unique strain-antibiotic-compound combinations. In this dataset, compounds more frequently exhibited synergy with known antibiotics than single-agent activity. We identified a compound, P2-56, and developed a more potent analog, P2-56-3, which potentiated rifampin (RIF) activity against Acinetobacter baumannii and Klebsiella pneumoniae . Using phenotypic assays, we showed P2-56-3 disrupts the outer membrane of A. baumannii . To identify pathways involved in the mechanism of synergy between P2-56-3 and RIF, we performed genetic screens in A. baumannii . CRISPRi-induced partial depletion of lipooligosaccharide transport genes ( lptA - D , lptFG ) resulted in hypersensitivity to P2-56-3/RIF treatment, demonstrating the genetic dependency of P2-56-3 activity and RIF sensitization on lpt genes in A. baumannii. Consistent with outer membrane homeostasis being an important determinant of P2-56-3/RIF tolerance, knockout of maintenance of lipid asymmetry complex genes and overexpression of certain resistance-nodulation-division efflux pumps – a phenotype associated with multidrug-resistance – resulted in hypersensitivity to P2-56-3. These findings demonstrate the immense scale of phenotypic antibiotic combination screens using DropArray and the potential for such approaches to discover new small molecule synergies against multidrug-resistant ESKAPE strains. Significance Statement: There is an unmet need for new antibiotic therapies effective against the multidrug-resistant, Gram-negative ESKAPE pathogens. Combination therapies have the potential to overcome resistance and broaden the spectrum of existing antibiotics. In this study, we use DropArray, a massively parallel combinatorial screening tool, to assay more than 1.3 million combinations of small molecules against the Gram-negative ESKAPE pathogens, Acinetobacter baumannii , Klebsiella pneumoniae , and Pseudomonas aeruginosa . We discovered a synthetic small molecule potentiator, P2-56, of the antibiotic rifampin effective in A. baumannii and K. pneumoniae . We generated P2-56-3, a more potent derivative of P2-56, and found that it likely potentiates rifampin by compromising the outer membrane integrity. Our study demonstrates a high-throughput strategy for identifying antibiotic potentiators against multidrug-resistant bacteria.